BPG is committed to discovery and dissemination of knowledge
Review
Copyright: ©Author(s) 2026.
World J Clin Oncol. Nov 24, 2026; 17(11): 127405
Published online Nov 24, 2026. doi: 10.5306/wjco.127405
Table 1 Representative screening and diagnostic metrics of sarcopenia
Metrics
Summary
Methodology
Asian/AWGS
Western/EWGSOP
Cut-off for men
Cut-off for women
Cut-off for men
Cut-off for women
Calf circumferenceThickest circumferenceTape measure< 34 cm< 33 cm< 34 cm1< 33 cm1
SMITotal skeletal muscle area at L3 divided by squared heightCT≤ -2 SD of young adults≤ -2 SD of young adults≤ -2 SD of young adults≤ -2 SD of young adults
PMITotal psoas muscle area at L3 divided by squared heightCT≤ -2 SD of young adults≤ -2 SD of young adults≤ -2 SD of young adults≤ -2 SD of young adults
ASMIAppendicular muscle mass divided by squared heightDXA< 7.0 kg/m2 (> 65 years)< 5.4 kg/m2 (> 65 years)< 7.0 kg/m2< 5.5 kg/m2
< 7.2 kg/m2 (for 50-64 years)< 5.5 kg/m2 (for 50-64 years)
ASMIAppendicular muscle mass divided by squared heightBIA< 7.0 kg/m2 (for > 65 years)< 5.7 kg/m2 (for > 50 years)< 8.50 kg/m2 for severe< 5.75 kg/m2 for severe
< 7.6 kg/m2 (for 50-64 years)< 10.75 kg/m2 for moderate< 6.75 kg/m2 for moderate
SARC-F5 items (muscle strength, assistance with walking, rise from a chair, climb stairs, and falls)Questionnaire≥ 4 points≥ 4 points≥ 4 points≥ 4 points
SARC-CalFSARC-F + calf circumferenceQuestionnaire, tape measure≥ 11 points≥ 11 points≥ 11 points1≥ 11 points1
Hand gripMaximum strength in 2-3 trialsHand dynamometer< 28 kg (for > 65 years)< 18 kg (> 65 years)< 27 kg< 16 kg
< 34 kg (for 50-64 years)< 20 kg (for 50-64 years)
Repeated chair stand testTotal time of 5 rises≥ 12 seconds (for > 65 years)≥ 12 seconds (for > 65 years)≥ 15 seconds≥ 15 seconds
≥ 10 seconds (for 50-64 years)≥ 10 seconds (for 50-64 years)
Gait speedSpeed in a 4- or 6-m walk< 1.0 m/second (for > 65 years)< 1.0 m/second (for > 65 years)< 0.8 m/second< 0.8 m/second
< 1.2 m/second (for 50-64 years)< 1.2 m/second (for 50-64 years)
SPPBStanding balance, gait speed, and chair-stand ability≤ 9 points (full score: 12)≤ 9 points (full score: 12)≤ 8 points (full score: 12)≤ 8 points (full score: 12)
Table 2 Summary of the safety and efficacy of treatments for colorectal cancer according to the three sex, seniors, and sarcopenia
Outcome
Setting
Women (vs men)
Fit, aged (vs younger)
Sarcopenia/reduced skeletal muscle (vs no sarcopenia)
SafetyPalliative chemotherapyIncreased gastrointestinal and hematological toxicities (5-FU, oxaliplatin, irinotecan)Increased diarrhea and neutropenia (5-FU, oxaliplatin, irinotecan)Increased neurological, gastrointestinal and hematological toxicities
Increased nausea (trifluridine/tipiracil)No difference (trifluridine/tipiracil)Frequent DLT (5-FU, oxaliplatin)
No difference (anti-VEGF)Increased thrombocytopenia (bevacizumab)Frequent DLT (regorafenib)
No different toxicity (anti-EGFR)No different toxicity (fruquintinib)
Increased fatigue, hypertension, skin toxicity, and anorexia (regorafenib)Increased diarrhea, frequent body weight loss (aflibercept)
No different toxicity (T-Dxd)No different toxicity (regorafenib)
Severer irAEs (ICIs)
ChemoradiotherapyFrequent interruption and discontinuationFrequent dose reductionProbable increased cystitis and thrombocytopenia
Increased diarrhea, perianal dermatitis, and hematological toxicitiesNo different toxicity
Adjuvant chemotherapyFrequent dose reduction (5-FU, oxaliplatin). Decreased completion rate (oxaliplatin)No different toxicity (5-FU)Decreased completion rate (oxaliplatin)
Probable increased toxicity (oxaliplatin)Frequent DLT (oxaliplatin)
EfficacyPalliative chemotherapyComparable PFS and OS (5-FU, oxaliplatin)Comparable RR and OS (5-FU)Poorer PFS and OS (5-FU, oxaliplatin)
Comparable PFS and OS (ICIs)Comparable RR and undermined survival benefit (oxaliplatin, irinotecan)
Comparable PFS and OS (trifluridine/tipiracil)
Comparable PFS and undermined survival benefit (bevacizumab)
Comparable OS (ramucirumab, aflibercept, fruquintinib)
Comparable RR and PFS (anti-EGFR)
Comparable RR and PFS (T-Dxd)
No survival benefit (pembrolizumab)
Comparable PFS (nivolumab + ipilimumab)
ChemoradiotherapyComparable tumor regression and pathological responseComparable tumor regression and pathological responseUndetermined impact on response
Adjuvant chemotherapyBetter DFS, RFS, and OS (5-FU, oxaliplatin)Comparable survivals (5-FU)Undetermined survival benefit (5-FU, oxaliplatin)
Undetermined survival benefit (oxaliplatin)


Write to the Help Desk